Venlafaxine extended release for the treatment of patients with premature ejaculation

Basit Öğe Kaydı
dc.authorwosidkılıç, süleyman/AAO-2348-2020
dc.contributor.authorKiliç, S
dc.contributor.authorErgin, H
dc.contributor.authorBaydinç, YC
dc.date.accessioned2024-08-04T20:13:45Z
dc.date.available2024-08-04T20:13:45Z
dc.date.issued2005
dc.departmentİnönü Üniversitesien_US
dc.description.abstractIn this study, we aimed at evaluating the efficacy and safety of venlafaxine extended release 75 mg, a serotonin and noradrenaline reuptake inhibitor, in the treatment of patients with premature ejaculation. Thirty-one patients with intravaginal ejaculation latency of less than 2 min received venlafaxine XR (75 mg/day) or placebo during a 2-week period for each agent with a washout period of 1 week between agents. Efficacy was assessed for each agent with changes in ejaculation latency measured with a stopwatch and sexual satisfaction scores of patients and partners. Side-effects, pre- and post-treatment levels of biochemical and spermiogram parameters, follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin and total testosterone were recorded for each agent. Statistical analysis was performed on 21 patients. After 2 weeks of treatment with placebo and venlafaxine, ejaculation latency time was significantly increased from 60.1 +/- 39.1 to 126.9 +/- 98.3 sec and to 178.1 +/- 122.8 sec, respectively (p < 0.0001 for each one). However, the difference between the two agents was insignificant (p = 0.144). Venlafaxine and placebo increased sexual satisfaction scores of both patients and partners similarly, no statistically significant difference was found between them in this respect. The incidence of side-effects with venlafaxine was indifferent than that of placebo (p > 0.1) except nausea (p = 0.035). Both agents did not change the blood and spermiogram parameters significantly, except FSH increases. Short-term use of venlafaxine XR 75 mg has only a placebo effect on ejaculation latency and sexual satisfaction scores, therefore, is not appropriate for the patients with premature ejaculation. Further dose-time studies are required to draw final conclusions on the inefficacy of this drug in premature ejaculation.en_US
dc.identifier.doi10.1111/j.1365-2605.2005.00507.x
dc.identifier.endpage52en_US
dc.identifier.issn0105-6263
dc.identifier.issn1365-2605
dc.identifier.issue1en_US
dc.identifier.pmid15679621en_US
dc.identifier.scopus2-s2.0-13444251652en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage47en_US
dc.identifier.urihttps://doi.org/10.1111/j.1365-2605.2005.00507.x
dc.identifier.urihttps://hdl.handle.net/11616/93806
dc.identifier.volume28en_US
dc.identifier.wosWOS:000226573300007en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofInternational Journal of Andrologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectejaculation latencyen_US
dc.subjectpremature ejaculationen_US
dc.subjectsexual satisfactionen_US
dc.subjectvenlafaxineen_US
dc.titleVenlafaxine extended release for the treatment of patients with premature ejaculationen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu